Targeting mTOR in HIV-Negative Classic Kaposi's Sarcoma
- PMID: 18509482
- PMCID: PMC2391286
- DOI: 10.1155/2008/825093
Targeting mTOR in HIV-Negative Classic Kaposi's Sarcoma
Abstract
A 66-year old female with HIV-negative classic Kaposi's sarcoma responded to mTOR targeting by rapamycin. The response was well documented by PET-CT. This case provides supporting evidence that the mTOR pathway may be important in the tumorigenesis of KS and that rapamycin may have activity in this disease.
Figures
References
-
- Brash DB, Bale AE. Molecular biology of skin cancer. In: DeVita VT Jr., Hellman S, Rosenberg S, editors. Cancer Principles and Practice of Oncology. Philadelphia, Pa, USA: Lippincott Williams & Wilkins; 2000. pp. 1971–1975. chapter 41.
-
- McCaffrey P. Sirolimus does double duty after organ transplantation. The Lancet Oncology. 2005;6(5):page 261. - PubMed
-
- Mohsin N, Budruddin M, Pakkyara A, et al. Complete regression of visceral Kaposi’s sarcoma after conversion to sirolimus. Experimental and Clinical Transplantation. 2005;3(2):366–369. - PubMed
-
- Vasanawala MS, Wang Y, Quon A, Gambhir SS. F-18 fluorodeoxyglucose PET/CT as an imaging tool for staging and restaging cutaneous angiosarcoma of the scalp. Clinical Nuclear Medicine. 2006;31(9):534–537. - PubMed
-
- Dupont P, Warrens AN. The evolving role of sirolimus in renal transplantation. QJM. 2003;96(6):401–409. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
